Ranibizumab and bevacizumab for neovascular age-related macular degeneration (Q24616209)

3

Maureen G

Maguire

1 reference

15 January 2024

Gui-shuang Ying

4

Gui-shuang

Ying

1 reference

15 January 2024

Juan E Grunwald

5

Juan E

Grunwald

1 reference

15 January 2024

Stuart L Fine

6

Stuart L

Fine

1 reference

15 January 2024

Glenn J Jaffe

The New England Journal of Medicine

7

0 references

language of work or name

English

0 references

publication date

19 May 2011

0 references

published in

0 references

volume

364

0 references

page(s)

1897-908

0 references

issue

20

0 references

cites work

Longitudinal data analysis for discrete and continuous outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

Ranibizumab for neovascular age-related macular degeneration

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

Incorporation of clustering effects for the Wilcoxon rank sum test: a large-sample approach

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157322

Identifying and eliminating the roadblocks to comparative-effectiveness research

28 November 2018

1 reference

12 December 2020

New visual acuity charts for clinical research

1 reference

12 December 2020

Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study

1 reference

12 December 2020

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1102673

1 reference

129978

129978

1 reference

1 reference

1 reference